nach oben

Current Psychiatry Reports

Erschienen in:

01.10.2014 | Attention-Deficit Disorder (A Rostain, Section Editor)

Managing the Risks of ADHD Treatments

verfasst von: Benjamin N. Schneider, Michael Enenbach

Erschienen in: Current Psychiatry Reports | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Pharmacotherapy of attention deficit-hyperactivity disorder (ADHD) is a well-established and effective treatment modality. However, ADHD medications are not without side effects. Understanding the prevalence of adverse events and effective management of risks associated with stimulants and other medications used to treat ADHD is central to broad applicability and effective treatment. This review discusses the literature on the prevalence of adverse events and management strategies employed. We searched online MEDLINE/PubMed and Cochrane databases for articles using several keywords relating to adverse events associated with ADHD medication management. We discuss the relevant data on the significance and prevalence of side effects and adverse events, highlight recent updates in the field, and suggest approaches to clinical management.

Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–8.PubMedCrossRef

2.•

Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012;10:99. A notable review in that it focused on long-term outcomes in which ADHD treatments were shown to reduce the negative impact of ADHD. PubMedCrossRefPubMedCentral

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch. Gen. Psychiatry. 1999;56:1073–86.

4.•

Döpfner M, Ise E, Wolff Metternich-Kaizman T, Schürmann S, Rademacher C, Breuer D. Adaptive multimodal treatment for children with attention-deficit/hyperactivity disorder: an 18 month follow-up. Child Psychiatry Hum. Dev. 2014. An 18-month follow-up to the Cologne Adaptive Multimodal Treatment (CAMT) study showing that the initial advantage of combined treatment over behavioral treatment was no longer evident at 18 months.

Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894–921.PubMedCrossRef

Partridge B, Lucke J, Hall W. Over-diagnosed and over-treated: a survey of Australian public attitudes towards the acceptability of drug treatment for depression and ADHD. BMC Psychiatry. 2014;14:74.PubMedCrossRefPubMedCentral

Findling RL, Biederman J, Wilens TE, Spencer TJ, McGough JJ, Lopez FA, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005;147:348–54.PubMedCrossRef

8.•

Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry. 2011;50:978–90. Showed a small subset of children and adolescents may have a greater increase in pulse or blood pressure. Found it to be extremely rare for a child or adolescent to have a serious cardiovascular event during treatment with the risk being similar to that in people not receiving treatment. PubMedCrossRef

Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev. 2002;22:1107–31.PubMedCrossRef

10.

Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006;21:92–5.PubMedCrossRef

11.

Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008;47:189–98.PubMedCrossRef

12.•

Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74–85.e2. A notable paper in that it looks at the safety of combining psychostimulants and alpha-2-agonists for the treatment of ADHD. Combination treatment was shown to be effective, and no new safety concerns were presented. PubMedCrossRef

13.•

Roesch B, Corcoran M, Haffey M, Stevenson A, Wang P, Purkayastha J, et al. Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Drugs R D. 2013;13:53–61. Open-label study of adults comparin Intuniv, Concerta, or combination treatment. No significant drug-drug interactions were found. PubMedCrossRefPubMedCentral

14.•

Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, et al. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:147–56. Cohort analysis showing cardiovascular events were rare and not associated with stimulant use, suggesting the safety of ADHD medication treatment in young people without known risk factors. PubMedCrossRefPubMedCentral

15.

Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306:2673–83.PubMedCrossRefPubMedCentral

16.•

Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896–904. Large cohort study showing no evidence that current use of ADHD drugs was associated with increased risk of cardiovascular events. PubMedCrossRef

17.•

Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127:1102–10. Cohort study that looked at stimulants as well as atomoxetine showing the rate of cardiovascular events to be very low and not significantly higher than in control subjects. PubMedCrossRefPubMedCentral

18.

Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ. 2012;345:e4627.PubMedCrossRefPubMedCentral

19.•

Dalsgaard S, Kvist AP, Leckman JF, Nielsen HS, Simonsen M. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: A nationwide prospective cohort study. J. Child Adolesc. Psychopharmacol. 2014. Cohort study that looked at long-term effects of stimulants. Notable for the longer observation period.

20.

American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J. Dev. Behav. Pediatr. 2008;29:335.

21.

Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122:451–3.PubMedCrossRef

22.

Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Cardiac Congenital Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117:2407–23.PubMedCrossRef

23.•

Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54:227–46. A notable review on medication management of ADHD. Provides expert consensus of the members of the European ADHD Guidelines Group. PubMedCrossRef

24.

Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165:1475–88.PubMedPubMedCentral

25.

Cheng JYW, Chen RYL, Ko JSN, Ng EML. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacol (Berl). 2007;194:197–209.CrossRef

26.

Wang Y, Zheng Y, Du Y, Song DH, Shin Y-J, Cho SC, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007;41:222–30.PubMedCrossRef

27.

Biederman J, Spencer TJ, Monuteaux MC, Faraone SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr. 2010;157:635–40. 640.e1.PubMedCrossRefPubMedCentral

28.

Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:994–1009.PubMed

29.

Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol. 2004;14:65–73.PubMedCrossRef

30.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:E105.PubMedCrossRef

31.

Konofal E, Lecendreux M, Cortese S. Sleep and ADHD. Sleep Med. 2010;11:652–8.PubMedCrossRef

32.

Tjon Pian Gi CV, Broeren JPA, Starreveld JS, Versteegh FGA. Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study. Eur J Pediatr. 2003;162:554–5.PubMedCrossRef

33.

James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry. 2004;65:752–5.PubMedCrossRef

34.

Cortese S, Konofal E, Lecendreux M, Arnulf I, Mouren M-C, Darra F, et al. Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Sleep. 2005;28:1007–13.PubMed

35.

Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am. 2011;58:99–120. xi.PubMedCrossRef

36.

Roessner V, Robatzek M, Knapp G, Banaschewski T, Rothenberger A. First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol. 2006;48:616–21.PubMedCrossRef

37.

Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48:884–93.PubMedCrossRefPubMedCentral

38.

Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2011;50:9–21.PubMedCrossRef

39.

Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31:328–41.PubMedCrossRefPubMedCentral

40.•

Molina BSG, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, et al. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013;52:250–63. Notable follow-up to the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder looking at the relationship between medication and subsequent substance use disorder. Medication for ADHD did not impact future substance use or substance use disorders. PubMedCrossRefPubMedCentral

41.

APA. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.

42.

Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179–85.PubMedCrossRef

43.•

Groenman AP, Oosterlaan J, Rommelse NNJ, Franke B, Greven CU, Hoekstra PJ, et al. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. Br J Psychiatry. 2013;203:112–9. Study in which stimulant use, especially at an earlier age, seemed to reduce the risk of future substance use disorders. PubMedCrossRef

44.

Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:21–31.PubMedCrossRef

45.

McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction. 2005;100:96–106.PubMedCrossRef

46.

Lakić A. Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder. Vojnosanit Pregl. 2012;69:201–4.PubMedCrossRef

47.

Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am. 1992;15:191–222.PubMed

48.

Barkley RA. The effects of methylphenidate on the interactions of preschool ADHD children with their mothers. J Am Acad Child Adolesc Psychiatry Elsevier. 1988;27:336–41.CrossRef

49.

Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1294–303.PubMedCrossRef

50.•

Childress AC, Arnold V, Adeyi B, Dirks B, Babcock T, Scheckner B, et al. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial. J Atten Disord. 2014;18:123–32. A notable outpatient clinical trial that found lisdexamfetamine dimesylate improved both ADHD symptoms and emotional lability. PubMedCrossRef

51.

Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics. 2009;123:611–6.PubMedCrossRef

52.

Goldsmith M, Singh M, Chang K. Antidepressants and psychostimulants in pediatric populations: is there an association with mania? Paediatr Drugs. 2011;13:225–43.PubMedCrossRefPubMedCentral

53.

Davis SM, Katusic SK, Barbaresi WJ, Killian J, Weaver AL, Ottman R, et al. Epilepsy in children with attention-deficit/hyperactivity disorder. Pediatr Neurol. 2010;42:325–30.PubMedCrossRefPubMedCentral

54.

Fosi T, Lax-Pericall MT, Scott RC, Neville BG, Aylett SE. Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. Epilepsia. 2013;54:2071–81.PubMedCrossRef

55.•

Santos K, Palmini A, Radziuk AL, Rotert R, Bastos F, Booij L, et al. The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies. Dev Med Child Neurol. 2013;55:654–60. Pilot study evaluating safety and efficacy of methylphenidate in a population with difficult-to-treat epilepsy. PubMedCrossRef

56.

Kelly BD, Lundon DJ, McGuinness D, Brady CM. Methylphenidate-induced erections in a prepubertal child. J Pediatr Urol. 2013;9:e1–2.PubMedCrossRef

57.

Cakin-Memik N, Yildiz O, Sişmanlar SG, Karakaya I, Ağaoğlu B. Priapism associated with methylphenidate: a case report. Turk J Pediatr. 2012;52:430–4.

58.

Husár M, Zerhau P. Priapism in childhood—case report of 14-year-old boy. Rozhl Chir. 2006;85:329–30.PubMed

59.

Schwartz RH, Rushton HG. Stuttering priapism associated with withdrawal from sustained-release methylphenidate. J Pediatr. 2004;144:675–6.PubMedCrossRef

60.

Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. J Psychopharmacol. 2014;28:204–11.PubMedCrossRef

61.

Agosti V, Chen Y, Levin FR. Does attention deficit hyperactivity disorder increase the risk of suicide attempts? J Affect Disord. 2011;133:595–9.PubMedCrossRefPubMedCentral

Titel: Managing the Risks of ADHD Treatments
verfasst von: Benjamin N. Schneider
Michael Enenbach
Publikationsdatum: 01.10.2014
Verlag: Springer US
Erschienen in: Current Psychiatry Reports / Ausgabe 10/2014
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-014-0479-3

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Meaning-Centered Psychotherapy: A Form of Psychotherapy for Patients With Cancer

Circadian Clock and Stress Interactions in the Molecular Biology of Psychiatric Disorders

Mild Cognitive Impairment: Diagnosis, Longitudinal Course, and Emerging Treatments

Bereavement: Course, Consequences, and Care